FDA Inspection 1014825 — Amgen, Inc.

Amgen, Inc. — FEI 2026154

The FDA completed an inspection of Amgen, Inc. on Apr 19, 2017 in Thousand Oaks, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI)
End Date
Apr 19, 2017
Fiscal Year
2017
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Thousand Oaks, CA (United States)

Additional Details

Sponsor, Contract Research Organization

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.